From: Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Treated Population
(N = 19)
Prior Therapies − Median (Range)
1 (0–6)
N (%)
Chemotherapy
2 (11)
Immunotherapy
1 (5)
G-CSF
3 (16)
Investigational Agent/Drug
Erythropoietin
10 (53)
Steroids
Vitamins
Lenalidomide